Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

Abstract

The addition of bevacizumab to oxaliplatin, fluorouracil, and leucovorin improves survival duration for patients with previously treated metastatic colorectal.

Factors Affecting Prognosis in Metastatic Colorectal Cancer Patients

“…It was reported that, in mCRC patients who have not treated before, adding bevacizumab to FOLFIRI regimen prolonged OS for 4.7 months and enhanced treatment response ratios about % 10. In mCRC patients, who have treated before, adding bevacizumab to oxaliplatin-based therapy achieved significantly prolonged survival rates, however, in patients who received this combination in first-line therapy, there was any significant enhancement in survival (Giantonio et al, 2007;Saltz et al, 2008).…”

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy

“…The clinical profile of off-label oxaliplatin is being assessed in patients with: (1) gastric, gastroesophageal or gastrointestinal carcinomas, most often in the context of either the so-called XELOX (capecitabine plus oxaliplatin) 155,156 or FOLFOX (folinic acid plus 5-fluorouracil plus oxaliplatin) 157 NCT02195180; NCT02241551; NCT02243358; NCT02244489; NCT02311439); (5) breast carcinoma, who receive oxaliplatin as a standalone therapeutic agent (NCT02077998); and (6) biliary tract or gallbladder carcinoma, who are treated with the GEMOX regimen plus a MEK inhibitor 163 (NCT02105350) ( Table 4).…”

Efficacy and Safety of Bevacizumab in Chinese Patients with Metastatic Colorectal Cancer

“…In a study of second-line treatment of mCRC, the E3200 clinical trial showed that bevacizumab in combination with FOLFOX4 comprehensively improved the ORR, PFS and OS of patients with mCRC in comparison with the FOLFOX4 regimen alone (Giantonio et al, 2007). The ML18147 study of bevacizumab cross-line treatment demonstrated that after first-line bevacizumabbased treatment had been changed to a second-line chemotherapy regimen, the continued use of bevacizumab still significantly improved the primary endpoint (OS) (Bennouna et al, 2013) of the study.…”